Protherics remains at buy for Jefferies

Jefferies & Co., Inc. analyst Robin Campbell reiterated Protherics plc at a buy and updated the price target to 150p from 170p. Campbell said that investors should draw comfort that the company's partner, AstraZeneca, is determined to do the best quality clinical development for CytoFab in treating severe sepsis. Shares of the Runcorn, U.K.-based biopharmaceutical company were down 3.50p, or 4.01% at 83.75p on volume of 4,347,200 shares versus the three-month running average of 437,824 shares. (London: PTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.